PTC THERAPEUTICS, INC.

(PTCT)
  Rapport
Temps Différé Nasdaq  -  22:00 29/06/2022
40.40 USD   +1.15%
23/06PTC THERAPEUTICS, INC. : RBC Capital Markets confirme sa recommandation neutre
ZM
21/06PTC Therapeutics affirme que l'essai de Translarna confirme les avantages du traitement ; les actions sont en hausse.
MT
09/06PTC Therapeutics, Inc. nomme Alethia Young à son conseil d'administration
CI
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
ETFs positionnés sur PTC THERAPEUTICS, INC.ETFs et Trackers avec Trackinsight
ETF PoidsVar. 5joursRatingGéographie
SPDR S&P Biotech ETF - USD0.93%5.75%Etats Unis
IShares Nasdaq US Biotechnology (D) - USD0.25%2.41%Etats Unis
IShares Nasdaq US Biotechnology - USD0.25%2.29%Etats Unis
IShares Biotechnology ETF - USD0.24%4.91%-NC
IShares Russell 2000 Growth ETF - USD0.2%3.32%Etats Unis
IShares Morningstar Small-Cap Growth ETF -...0.16%2.12%-NC
Xtrackers Russell 2000 1C - USD0.09%2.16%Etats Unis
IShares Russell 2000 ETF - USD0.09%2.56%Etats Unis
IShares Morningstar Small-Cap ETF - USD0.07%2.68%-NC
IShares Core S&P Total U.S. Stock Market E...0.01%1.67%Etats Unis
IShares Russell 3000 ETF - USD0.01%1.67%Etats Unis
IShares Core MSCI All Country World ex Can...0%0.24%Monde
IShares Core MSCI All Country World ex Can...0%0.00%-Monde



Copyright © 2009 Morningstar. All Rights Reserved. The information, data and opinions expressed (“Information”) and contained herein: (1) are proprietary to Morningstar and/or its content providers and are not intended to represent investment advice or recommendation to buy or sell any security; (2) may not be copied or distributed without express license to do so; and (3) are not warranted to be accurate, complete or timely. Morningstar reserve its rights to charge for access to these Ratings and/or Rating report. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this Rating, Rating Report or Information contained therein.
Graphique PTC THERAPEUTICS, INC.
Durée : Période :
PTC Therapeutics, Inc. : Graphique analyse technique PTC Therapeutics, Inc. | Zone bourse
Graphique plein écran
Evolution du Compte de Résultat
Consensus
Vente
Achat
Recommandation moyenne ACCUMULER
Nombre d'Analystes 11
Dernier Cours de Clôture 40,40 $
Objectif de cours Moyen 49,10 $
Ecart / Objectif Moyen 21,5%
Révisions de BNA
Secteur et Concurrence
Var. 1janvCapi. (M$)
PTC THERAPEUTICS, INC.1.43%2 882
GILEAD SCIENCES, INC.-13.95%78 370
VERTEX PHARMACEUTICALS27.66%71 701
REGENERON PHARMACEUTICALS, INC.-5.37%64 391
WUXI APPTEC CO., LTD.-14.46%44 027
BIONTECH SE-44.93%34 504